Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That sucks that you don't have CLNE.. When TOTAL SA bought 50.8 million shares back in May 2018 that would of been your signal to get back in..
Fun times to be a shareholder Jersey.. Glad you are riding IQST to the moon with us :)
WPRT?
Up 0.53 afterhours.. This is awesome to be invested in CLNE, WPRT, and GEVO
I am glad we along with kettle were scooping shares of CLNE and WPRT when no one wanted to buy..
UPS always report good earnings plus always give good divvy
Solid as rock today.. Very NICE!!
True that and I am expecting a contract or two to be announced this year.. Lets hope it sooner than later..
Getting closer to her PT.. Hopefully their earnings will be better than expected during last quarter..
Up 12%!! Not too shabby eh.. GO SOS!!!
Nevermind just filled
WTF my order of 700000 shares just been sitting there and not getting filled..
I like the sounds of $150 but I agree with ronsthc.. If bitcoin goes to $50k-100K that $150 pps might turned into reality..
Gearing up for another run.. Riding free shares now.. Let's go GEVO!!!
That's great!! Hope it continue to climb next week
Could be the start of a long run.. Lets GO SOS!!
SOS is a mover today..Up 22%
That's what I did earlier 2200 shares @ $2.69
I’ve done that to all my stocks actually I started doing that 10yrs ago..I did put a sell order at $100 as soon as I bought GEVO..
I am looking at $10+ by end of year..
That $14 was gone in a blink of an eye and went back to $13 lol
What a nice 360!!
Key Corporate Highlights
As of January 22, 2021, Gevo had approximately $535 million of cash and virtually no debt. Gevo intends to use its cash to fund capital projects, working capital and for general corporate purposes.
Gevo now has enough cash to fund 100% of the equity investment that is expected for Net-Zero 1. Gevo may bring in appropriate strategic or financial partners as equity investors if it is in Gevo’s interests to do so. Gevo expects to establish Net-Zero 1 in a special purpose entity. The full financing of Net-Zero 1 can only be completed after the front-end engineering phase is completed.
As of January 22, 2021, Gevo had approximately 198 million shares of common stock issued and outstanding.
Gevo has approximately 48MGPY of contracts signed for a mix of jet fuel and renewable gasoline products, representing approximately $1.5 billion of revenue across the life of the contracts. If Gevo secures additional take-or-pay contracts, Gevo would have to acquire and develop additional Net-Zero production sites.
Gevo has optioned the right to purchase approximately 240 acres of land near Lake Preston, SD. This site is attractive because of its abundant sustainable corn supply, high protein feed demand, rail transportation, and renewable energy potential.
Gevo is planning to close and begin construction of its first RNG project in 2021 (the “NW Iowa Project”). The NW Iowa Project will produce RNG by using anaerobic digesters to convert manure from dairy cows into RNG. RNG production is expected to begin in 2022. Citigroup is arranging the debt financing. Gevo plans to sell most of the gas to the RNG market in California and use some of the biogas generated from this project at its renewable hydrocarbons plant, for example, at Lake Preston, Luverne, and/or another site.
Gevo hired Citigroup to assist the financing of the Net-Zero production facilities and the RNG project. The Net-Zero 1 financing process is dependent on completing the front-end engineering work, expected to be completed in December 2021. Gevo expects financing for Net-Zero 1 to close in the first half of 2022.
Key Initiatives for 2021
Complete front-end engineering work for Net-Zero 1 by year end of 2021.
Gevo anticipates signing take-or-pay contracts with additional customers in 2021. Additional contracts are expected to support additional Net-Zero projects (e.g., Net-Zero 2 and 3).
Secure additional plant sites for Net-Zero 2 and/or 3 to accommodate additional offtake agreements that Gevo may sign this year.
Close financing for Gevo’s NW Iowa Project and commence construction.
Secure investment agreements with strategic and financial project investors for Net-Zero projects if terms are attractiv
ENDRA Life Sciences Further Strengthens TAEUS(R) System Intellectual Property Protection with Issuance of 14th U.S. Patent
Tue, January 26, 2021, 5:00 AM
ANN ARBOR, MI / ACCESSWIRE / January 26, 2021 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued U.S. Patent 10898166 (the ‘166 patent) from the United States Patent & Trademark Office (USPTO). This new patent, titled "Systems and Methods for Imaging Biological Tissue Structures," defines a hybrid integrated ultrasound/ thermoacoustic system and method that locates and registers the ultrasound and thermoacoustic portions of the invention relative to one another.
The ‘166 patent complements ENDRA's U.S. patent 10028662, which relates to an ultrasound/thermoacoustic system and method that utilizes separate ultrasound/ thermoacoustic systems concurrently. In addition, it is the parent application to recent patents that have issued in Europe and China, European Patent 3294142B1 and Chinese patent ZL 2016 8 00267062, respectively.
"The ‘166 patent supports ENDRA's goal to develop applications for our proprietary TAEUS® technology in areas of high unmet clinical need and with no practical existing tools. It is a key step forward in the development of optimized hybrid ultrasound and thermoacoustic imaging systems for a wide variety of clinical applications, including Non-Alcoholic Fatty Liver Disease (NAFLD)," explained ENDRA's Chief Executive Officer, Francois Michelon. "Our IP portfolio continues to grow and currently stands at 80 assets, which we define as patents issued, filed, licensed or in preparation. As we advance TAEUS® commercial launch plans, it is essential to protect our valuable intellectual property in priority global markets."
ENDRA's commercialization of TAEUS® includes establishing clinical research partnerships worldwide, with an initial focus on Europe and the U.S. To date the company has established five research partnerships including two in Europe and three in the U.S. In December 2020 ENDRA renewed its collaboration agreement with the GE Healthcare unit of General Electric Company, extending the agreement's term by two years to December 16, 2022. GE Healthcare is the global leader in clinical ultrasound and has been ENDRA's partner since 2016.
TAEUS® is currently cleared for sale in countries that recognize the CE mark, including those in the European Union, and a 510(k) application has been submitted to the U.S. Food and Drug Administration.
About NAFLD
NAFLD is a condition closely associated with obesity, diabetes, hepatitis C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S. healthcare system over $100 billion annually. NAFLD is often asymptomatic and if left untreated, can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical, and include expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations regarding commercializing the TAEUS® device, establishing evaluation reference sites and initial sales in Europe, receipt of U.S. Food and Drug Administration regulatory approval and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com
SOURCE: ENDRA Life Sciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/625884/ENDRA-Life-Sciences-Further-Strengthens-TAEUSR-System-Intellectual-Property-Protection-with-Issuance-of-14th-US-Patent
Offering just killed off the momentum.. I guess its better to get this crap out now rather than after the outcome of their lawsuits..
Healthy retrace to cool of the RSI.. Watch that $20 its coming
Damn this came back to life and really I thought this was dead :)
I agree and soon to be millions of users.. I can't wait to see their earnings not expecting much tho except increased in volume they delivered during Q4
ROI is 1025% best and fastest stock return I've ever own in a short period of time.. GO GEVO!
Liking the ride in to the atmosphere with my free 15K shares.. GO SNPW!!
Just learned about TRXC last weekend..
I also got 2200 shares paid $3.89 wish I have your entry point but no worries this is a good long term.. good luck
Nice update cat..thanks
Nice close on CLNE and IQST my friend.. I am glad you're happy.. I wish you got on GEVO my ROI is 998% so far..
I also made a trade this am on SNPW bought 30k at $0.10 sold half at $0.20 to get my initial back now riding 15k free shares.. Good trade nonetheless
ROI on my GEVO is 998%..Frigging mind-boggling
Sold half of my 30K to get my $ back and now riding free shares.. A nice trade nonetheless..
Close to hitting that $15.. It would be so gnarly if GEVO hits $20 at the end of month..
Thumbs up on your post kettle.. Loving this company more and more as I ride my free shares in to the atmosphere..
Woow this is unreal!!! Almost doubled my $ and just bought it this am..
I sold 180 shares on my ameriturd to get my original investment back so now I am riding 1820 free shares.. Lets go GEVO!!
Thank you!!
I took off all my original investment now riding on free shares..